EBV BRLF-1 148-156 (HLA-A*03:01) RVRAYTYSK

#

The EBV BRLF-1 134–142 peptide (ATIGTAMYK; epitope ID: 5002) is a well-characterized CD8+ T-cell target derived from the Replication and Transcription Activator (RTA / BRLF-1; UniProt: P03209) of Epstein-Barr Virus (EBV / Human Herpesvirus 4). As an immediate-early lytic phase protein, BRLF-1 initiates viral reactivation, making this nonamer sequence a crucial marker for tracking lytic cytotoxic T-cell memory. Featuring the amino acid sequence ATIGTAMYK, this peptide is restricted by HLA-A*11:01 and represents a structurally solved model antigen (PDB ID: 6JOZ) for dissecting peptide-MHC binding dynamics and TCR engagement.Key Features & BenefitsHLA-A*11:01 Restriction: High-affinity anchor nonamer optimized for precise CD8+ cytotoxic T-cell activation, tetramer generation, and immunomonitoring in HLA-A*11:01-positive donor cohorts.Structurally & Functionally Benchmark-Validated: Backed by over 17 peer-reviewed publications, 24 functional T-cell assays, 7 MHC ligand binding studies, and a published 3D crystal structure (PDB: 6JOZ).Core Control Component: Integrated as an essential reference constituent in peptides&elephants' EBV Control Peptide Pool (>95% HPLC), CEF (Classic) Peptide Pool (>95% HPLC), and CEF (Advanced) Peptide Pool (>95% HPLC).ApplicationsEBV Lytic Phase Immunomonitoring: Quantifies functional cytotoxic CD8+ T-cell memory (IFN-gamma, TNF-alpha, CD107a) against immediate-early viral reactivation in human PBMCs.Recall Controls & Assay Standardization: Serves as a gold-standard positive control in ELISpot, Fluorospot, and Intracellular Cytokine Staining (ICS) assays.Structural & Biophysical Research: Ideal reference ligand for HLA-A*11:01 docking studies, TCR cross-reactivity mapping, and structural biology applications.

The EBV BRLF-1 28–37 peptide (DYCNVLNKEF; epitope ID: 10856) is a well-characterized CD8+ T-cell epitope derived from the Replication and Transcription Activator (RTA / BRLF-1; UniProt: P03209) of Epstein-Barr Virus (EBV / Human Herpesvirus 4).As an immediate-early lytic cycle protein, BRLF-1 triggers viral reactivation, making this decamer sequence an essential target for detecting early cytotoxic T-lymphocyte responses. Featuring the amino acid sequence DYCNVLNKEF, this peptide is presented via HLA-A*24:02—an allele highly prevalent in East Asian populations as well as Caucasian cohorts—providing critical coverage for global immune-profiling assays.Key Features & BenefitsHLA-A*24:02 Restriction: High-affinity anchor decamer optimized for precise CD8+ cytotoxic T-cell activation, tetramer generation, and TCR profiling in HLA-A*24:02-positive cohorts.Extensively Validated Target: Backed by a solid evidence base of 12 peer-reviewed publications, 15 functional T-cell assays, and MHC ligand binding studies.Core Control Component: Integrated as an essential reference constituent in peptides&elephants' CEF (Advanced) Peptide Pool (>95% HPLC), CEF (Classic) Peptide Pool (>95% HPLC), and EBV Control Peptide Pool (>95% HPLC).High Chemical Quality: Manufactured by peptides&elephants under strict quality control standards to guarantee high batch-to-batch reproducibility, exceptional solubility, and reliable assay performance.ApplicationsEBV Lytic Phase Immunomonitoring: Measures functional CD8+ Effector and Effector Memory T-cell activation (IFN-gamma, TNF-alpha, CD107a) against immediate-early EBV reactivation in human PBMCs.Recall Controls & Assay Standardization: Serves as a positive control in ELISpot, Fluorospot, and Intracellular Cytokine Staining (ICS) assays.MHC Multimer & Tetramer Staining: Ideal reference ligand for folding HLA-A*24:02 peptide-MHC complexes to isolate and enumerate antigen-specific CD8+ T cells.